Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of SBRT followed by atezolizumab + tiragolumab in treatment-naive metastatic non-small cell lung cancer
KCT0006529Phase 2Active, not recruiting
- Sponsor
- Yonsei University Health System
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, tiragolumab in non-small cell lung cancer (NSCLC), sponsored by Yonsei University Health System. Started Jul 2022; status: active, not recruiting.
02
Drugs
atezolizumabtiragolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0006529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006529.